Although lung cancer patients who experienced rapid, durable, complete or partial responses to TKI therapy have been found to harbor somatic mutations in the EGFR gene16, it has also been demonstrated that many of the patients who had received first generation of TKI treatment for 6 to 10 months will develop resistance to TKIS. This evidence concerns the gene EGFR and lung carcinoma.